# A Single-center Clinical Trial of Bortezomib in Management of Immune Thrombocytopenia (ITP)

> **NCT03013114** · PHASE2 · UNKNOWN · sponsor: **Shandong University** · enrollment: 20 (estimated)

## Conditions studied

- Immune Thrombocytopenia

## Interventions

- **DRUG:** Bortezomib

## Key facts

- **NCT ID:** NCT03013114
- **Lead sponsor:** Shandong University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2017-01
- **Primary completion:** 2017-12
- **Final completion:** 2017-12
- **Target enrollment:** 20 (ESTIMATED)
- **Last updated:** 2017-01-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03013114

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03013114, "A Single-center Clinical Trial of Bortezomib in Management of Immune Thrombocytopenia (ITP)". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT03013114. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*